Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Viehbacher sees in Genzyme

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis's proposed acquisition of Genzyme, announced on 29 August, is a major acceleration of its diversification strategy, which has also seen the company building a presence in the consumer, generics and animal health markets. Simon King explains why Christopher Viehbacher, Sanofi's CEO, is wooing the industry's leading niche market player.

You may also be interested in...

Acquisitions pave the way to the patent cliff

The largest players in the this year's Scrip 100 ranking continue to implement a range of strategies to shift emphasis away from blockbuster-centric growth models and ensure greater insulation from generic competition. Datamonitor's Simon King explores the Scrip 100.

Is AstraZeneca Abbott's most likely merger partner?

Following the announcement on 19 October that Abbott Laboratories is to separate its prescription pharmaceutical unit from its other business units, speculation has turned to whether a rival big pharma player will make a move to acquire Abbott’s prescription portfolio, which is heavily focused on the anti-TNF biologic therapy Humira ( 20 October 2011).


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts